Asylia Announces Formation of Distinguished Scientific Advisory Board
HOUSTON, July 22, 2021 – Asylia Therapeutics (“Asylia”), a development-stage biotechnology company advancing novel
Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer and auto-immune diseases. Asylia’s platform centers on a drug pipeline capable of modulating antigen presentation to the immune system which has produced unprecedented anti-tumor responses across multiple cancer models.
Asylia Therapeutics is a private development stage biotechnology company committed to transforming scientific advances into safe and effective medicines for cancer and auto-immune diseases. Asylia’s platform centers on a drug pipeline capable of modulating antigen presentation to the immune system which has produced unprecedented anti-tumor responses across multiple cancer models.
Asylia is led by a seasoned team of entrepreneurs, scientific leaders in immunity, oncology and clinical trials, and biotech executives with experience in antibody drug and business development.
Stay up to date with the latest news from Asylia Therapeutics
HOUSTON, July 22, 2021 – Asylia Therapeutics (“Asylia”), a development-stage biotechnology company advancing novel
Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into
Houston, Texas. February 8, 2021 – Houston: the true third coast of innovation. Texas
Stay up to date with the latest news from Asylia Therapeutics
HOUSTON, July 22, 2021 – Asylia Therapeutics (“Asylia”), a development-stage biotechnology company advancing novel
Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into
Houston, Texas. February 8, 2021 – Houston: the true third coast of innovation. Texas